The HTC Rhyme

The HTC Rhyme is something of a delicate matter, as it is HTC's firstphone that is said to have been designed with a female audience in mind. Yet it comes in dull colours and looks quite a lot like every other HTC handset we’ve seen so far.

PENTAX Q-REVIEW

Let’s get one thing straight from the start. The Pentax Q is quite an incredible camera to behold. It’s tiny. But not only is it tiny, it also looks great.

NIKON 1 V1

Nikon has announced two new compact system cameras: the Nikon 1 V1 and the Nikon 1 J1. We got our hands on both new cameras today, so until we can bring you our Nikon 1 V1 review

The ULTra Personal Rapid Transit System

"Think of it as a horizontal lift," says Fraser Brown, managing director of ULTra, the company that has built a new way to travel to Heathrow Terminal 5 from the business car park

THREE MIFI HSPA

Three has updated its MiFi range with the new Huawei E586 complete with HSPA+, and we have managed to get our hands on one to test out all its mobile internet goodness

Saturday, October 23, 2010

Variety a Hit with Czech Beer Enthusiasts

The brewer that prides itself as the creator of the best and original lager is building up two local niches by broadening its offer of acclaimed non-alcoholic beer to include a semi-dark version and also tapping into craft beer interest with the further rollout of its distribution of beer via tanks.

Plzensky Prazdroj AS — theCzech brewer that created modern beer as we know it in 1842 when it first brewed a bottom-fermented, golden beer called Pilsner Urquell — this autumn has introducedBirell polotmavy, or semi-dark, non-alcoholic beer.
The introduction of Birell semi-dark follows Plzensky Prazdroj’s smaller Czech competitor Rodinny PivovarBernard, which produces versions of non-alcoholic beer not limited to the typical pseudo-lager format, but also including a semi-dark version and a unique non-alcoholic brew with extract and aroma from plums.
Plzensky Prazdroj’s new semi-dark Birell builds on the success of the original light-colored version that took first place in the 2008 World Beer Cup in the non-alcoholic category, among other awards.
Demand for Birell is rising quickly and at present accounts for 4% of Plzensky Prazdroj’s total revenue, up from less than 1% just a few years ago.
For comparison, international export of Plzensky Prazdroj’s flagship Pilsner Urquell brand account for 10% to 15% of total revenue.
The brewery, owned by SABMiller PLC, also distributes its non-alcoholic beer in kegs to over 1,000 locations, so Czech and Slovak bars and restaurants can offer the drink on tap, a rarity in the global non-alcoholic beer market.
Douglas Brodman, Plzensky Prazdroj chairman and chief executive officer, told The Wall Street Journal in a recent interview that in the first 60 days of semi-dark Birell’s sales, demand more than doubled the brewer’s forecasts.
Birell differs from most other non-alcoholic beers globally because it uses unique yeast that doesn’t produce alcohol when fermenting. Typically brewers make non-alcoholic versions of beer by brewing in the standard fashion and later extracting alcohol after fermentation, pulling out flavor and body as well.
But unfortunately for the growing ranks of non-alcoholic beer aficionados globally, Plzensky Prazdroj produces the unique drink on license from Danish brewer Carlsberg, and the licensing agreements only allow Birell sales in the Czech Republic and Slovakia.
The Czech brewer is limited in yet another of its key marketing strategies: tank beer.
Around the world draft beer is distributed in kegs, and typically such beer is pasteurized, meaning it is heated to near but below the boiling point to kill microbial growth and extend shelf life, but also killing friendly, alcohol- and flavor-developing yeast.
But some enterprising Czech companies are reducing production, packaging and distribution costs by distributing their beer in tanker-trucks directly to pubs where the beer is pumped into large, vacuum sealed storage tanks for immediate consumption.
Several Czech brewers besides Plzensky Prazdroj are selling beer in tanks in restaurants, including the Krusovice brewery, owned by Heineken, and Czech state-owned Budejovicky Budvar NP, the brewer which for centuries has been producing beer called Budweiser, named after the city Ceske Budejovice, or Budweis in German, where the brewery is located.
Draft beer sold from tanks is a hit with beer enthusiasts, in part because the brew is unpasteurized, served fresh while the yeast is still alive and developing a richer taste in the tanks that hold the equivalent of either 1,000 pints or 2,000 pints.
Restaurant owners are especially keen to have the tanks visible to beer drinkers, Brodman said. The tanks are often enclosed in refrigerated spaces cut off from customer seating areas not by brick or steel, but by thick glass partitions.
Brodman said Plzensky Prazdroj only delivers tank beer to pubs that serve up large-enough volumes to deplete an entire tank in three days.
Currently about 600 pubs and restaurants offer Plzensky Prazdroj’s beers in tanks. But for logistics reasons, only pubs located within a perimeter of roughly 300 kilometers from the brewery can offer tank beer.
Internationally, Prazdroj sells tank beer only in Slovakia, with six locations in Bratislava, and Austria, with one in Vienna.

'World's best gluten-free beer' released in the US


'World's best gluten-free beer' released in the US

On October 18, one of Spain's biggest brewers, Estella Damm, introduced its gluten-free "real beer tasting" Daura, originally Estrella Damm Apta Para Celíacos, to the US market.
Daura is presently available in twelve nations around the world (Australia, UK, Germany) and holds the title of "World's Best Gluten-Free Beer" for 2008 and 2009.
The makers explain their proprietary brewing process is what sets Daura apart from other beers in this category (Australia's O'Brien Brown Ale, Birra 76 Bi-Aglut by Heineken, Celia Saison by The Alchemist in Vermont).
 "The gluten protein [is stripped] from the barley malt, leaving only the 'real beer' taste.
"DAURA's gluten content level is less than 6 parts per million (ppm), far below the 20 ppm required for gluten free products, according to the Codex Alimentarious, the international food and drinks standard set by the World Health Organization and the United Nations Food and Agriculture Organization."
Justin Fisch, the marketing director of US Beverage, said "DAURA is a light, smooth and refreshing lager beer, which has been embraced by global beer lovers whether gluten intolerant or not." 
For more Daura tasting notes and ratings like "metallic cereal" and "Light caramel taste. Probably best Celiac beer I have had." 
A Daura 4-pack costs $7.99/€5.80 and can now be found in these American stores: Whole Foods, Publix, Harris Teeter, Total Wine & Spirits and BevMo.

Dr Pepper wins in customer satisfaction survey


That's the message from a closely watched survey of 1,000 soft drink shoppers conducted recently by Michigan-based American Customer Satisfaction Index. Soft drinks are one of the best-liked industries out of dozens covered by the national survey.
Pepsi dropped two points to 84 on a 100-point scale, placing it in a tie with Atlanta-based Coca-Cola Co. Dr Pepper Snapple claimed the top spot with an 85. The survey, conducted in June and July, asked questions about value for money, a topic increasingly relevant to purchases.
"Anytime we're in a state of a weakened economy, people are skittish about their spending," said David VanAmburg, managing director at ACSI, based in Ann Arbor, Mich. "In a down economy, [consumers] say, ‘Quality is nice, but I need to get a good value for my money.'"
Because soft drinks are so affordable, it's easy to switch brands if one desires. That makes the industry a case study in competitiveness and one of the perennial winners out of about 45 industries covered by ACSI, VanAmburg said. This year, the industry average score was 84 out of a possible 100. Only the electronics industry, with offerings such as flat-screen TVs and computers, scored higher with an 85. Airlines, by contrast, scored in the mid-60s.
Coca-Cola, PepsiCo and Dr Pepper "have to bend over backwards to please their customers, because the switching cost is basically zero," VanAmburg said. "This industry, it's not at all surprising, would have very, very high customer satisfaction."
Coca-Cola's score has held basically steady for four years. Dr Pepper has consistently ranked a point or two higher than its larger competitors in that span, possibly reflecting greater enthusiasm and loyalty among fans of the smaller brand, VanAmburg said.
"This is an industry where for the most part, there's not a lot of separation," said VanAmburg. "People who love Pepsi love Pepsi. People who love Coke love Coke. These companies know how to make their soft drinks. It's really just about preference."
Customer Satisfaction Scores Over Time:
Soft Drink Industry (2008, 2009, 2010) 83,  85,  84
Dr Pepper Snapple (2008, 2009, 2010) 87, 86, 85
Coca-Cola (2008, 2009, 2010) 85, 84, 84
PepsiCo (2008, 2009, 2010) 84, 86, 84
Source: ACSI

Self-examination - key to the fight against breast cancer

The fight against breast cancer begins with the individual's initiative to examine herself on regular basis, Ms Alberta Dela of the Cancer Unit of the Komfo Anokye Teaching Hospital, has stated. She said early detection is critical to the fight against the disease and advised women to frequently examine their breasts as a means of prevention.

Ms Dela was speaking at a District Forum to sensitise women on the effects of breast and cervical cancer as well as their rights to sexual reproductive health at Juaso in the Asante Akim South District. The forum, which was organised by the Department of Women under the auspices of the Ministry of Women and Children's Affairs, was sponsored by the United Nations Population Fund. The participants were educated on the effects of breast and cervical cancer, gender-based violence issues and sexual reproductive and maternal health rights.

Ms Dela entreated women to report any changes in their breasts to the nearest health facility for professional care but desist from self-medication.

She said though the cause of cancer was yet to be identified, women beginning their menopause and those who give birth after 35 years were more likely to be at risk and urged such women to avail themselves of breast screening regularly.

While commending the government for including breast and cervical cancer in ailments covered by the National Health Insurance, Miss Dela said it was imperative to include other forms of cancers because their treatments were very expensive. Mrs. Augustina Gyamfi, the Acting Ashanti Regional Director of Department of Women, in a presentation on gender-based violence, condemned the alarming rate of abuse against women and children in the home. She also spoke against the increasing rate of human trafficking, which most often involves children and called for stiffer punishment to deter perpetrators 22 

Detecting Breast Cancer Early Doctors Catch Cancer Earlier with Special MRI

A new kind of MRI machine helps doctors diagnose breast cancer earlier. Patients lie on their stomach and their breasts are placed in two coils, which focus radio waves and allow for more complete images that give a three-dimensional look inside the breast.

Two-hundred thousand women will be diagnosed with breast cancer this year in the United States. Mammograms, however, may not be the best way to detect it. Now, there's a new test to help doctors pinpoint and treat breast cancer.
Suzette Lipscomb knows how to get the most out of every moment and she plans to share most of those moments with her little girl, Ava. "I always wanted a little girl, but I was a little afraid that I may pass on some type of tendency toward the disease," Suzette says.
The disease she feared? Breast cancer. Her grandmother beat it and so did she. It wasn't easy though, during her battle she was forced to make a difficult decision. Suzette says, "I was trying to make a decision as to whether or not to remove both my breasts."
Richard Reitherman, a breast radiologist at CAD Imaging Sciences in White Plains, N.Y., used the new cadsciences breast imaging system to help decide which treatment would work best. For the test, patients lie on their stomach with their breasts in two coils, which help focus radio waves for more complete images.
"She and her surgeon know exactly how big the tumor is, so it gives her the best treatment," Dr. Reitherman says. For Suzette it showed her second breast was clear.
A dye injected into the patient helps pinpoint cancer and if chemotherapy treatments are working. In the scan, the red areas are cancer -- cancer that was missed in a mammogram. In fact, 20 percent of women who don't have the cad-sciences MRI will need a second surgery, something Suzette was able to avoid.
"I feel like the luckiest woman alive that not only did I have my cancer caught early enough that I'm alive, but that I was able to have a child," Suzette says.
Not all women are candidates for this cadsciences MRI. It's used for women who have already been diagnosed and need to know a course of action. It's also used for women who are high risk and have a family history of the disease. The procedure takes about 30 minutes; results are available 15 minutes later.
BACKGROUND: Women have a new imaging tool set to help diagnose breast cancer. The 3TP method generates a unique color-coded map by measuring changes (color and intensity) in contrast agent concentration in normal and cancerous tissues over time. It provides information that is not readily available from traditional mammography or MRI. In addition, the 3TP system is ergonomically designed to be comfortable for the patient, regardless of breast size.
HOW MRI WORKS: Magnetic resonance imaging uses radiofrequency waves and a strong magnetic field instead of X-rays to provide clear and detailed pictures of internal organs and tissues. These radio waves are directed at protons in hydrogen atoms -- one of the most abundant atoms in the human body, because of the body's high water content. The waves "excite" the protons, and when they "relax," they emit strong radio signals. A computer can turn those signals into a high-contrast image showing differences in the water content and distribution in various bodily tissues. It is becoming increasingly popular as an alternative to traditional X-ray mammography for the early diagnosis of breast cancer because women aren't exposed to the same radiation they experience with X-rays.
ABOUT BREAST CANCER: Breast cancer is a type of cancer in which cells in the breast become abnormal and grow and divide uncontrollably, eventually forming a mass called a tumor. Some tumors are benign, meaning that they do not invade other types of tissue, although if they become big enough, they can interfere with some bodily functions, such as the flow of blood or urine. Malignant tumors have cells that can invade nearby tissues. When a cancer "metastasizes," cells from the original tumor break off and travel to other parts of the body via the blood or lymph systems. More than 75 percent of breast cancers begin in the milk ducts within the breast. The next most common site is in the glandular tissue that makes the milk.
DO-IT-YOURSELF BREAST EXAM: Although it is not a substitute for regular tests by your doctor, women can perform a basic breast self-exam at home. In fact, more than 90 percent of all breast lumps are found by the women themselves. Breast tissue is shaped like a comma with the tail curving up toward the armpit, and normally has a lumpy feel. Because hormones can affect the breast tissue, the best time to examine your breasts is a few days after your period ends, when hormone levels are stable.

Cold-Activated Beer Bottles: Is Busch Light Onto Something?


Anheuser-Busch wants to heat up the competition by cooling down with new packaging. At a distributor meeting in New Orleans, the company revealed plans to unveil new cold-activated bottles for the Busch Light label that will turn blue when the temperature is optimal for drinking.
The "ice cold easy indicator," as it's called, isn't exactly original — it was just used on Coors Light bottles, which have mountains that turn blue, as the company says, "when it's as cold as the Rockies." The reaction from MillerCoors reps has been tepid: "I've heard that's been done before," one spokesperson remarked.
The temperature-sensitive packaging will be central to the bulk of Busch Light's advertising.
While it's a way to spend advertising dollars, I'm pretty sure one can already tell if beer is cold enough just by touching it. What do you think? Can you warm up to this idea?

California can't stop some Medicaid services without U.S. approval, judge rules

A Sacramento federal judge has ordered the state to keep providing adult dental, podiatric and chiropractic services to poor people in underserved rural areas until it gets permission from federal heath authorities to discontinue the benefits.
U.S. District Judge Frank C. Damrell Jr. ruled Wednesday that, while the services are not mandatory under the federal Medicaid program (Medi-Cal in California), the Legislature's decision to end them last year as a cost-saving measure was unlawful without federal approval.
Damrell issued an injunction barring further implementation of the change in the Medi-Cal plan until the state gets federal approval.
Anthony Cava, spokesman for the state Department of Health Care Services, said Thursday the department, which oversees the Medi-Cal program for people below the poverty line, will abide by the judge's order.
He said the department will resume reimbursements to qualified health care centers and rural health clinics for the services.


How To Win Doctors And Influence Prescriptions


Mathew Webb left a sales job in menswear for a sales job in pharmaceutical drugs 10 years ago and suddenly found himself surrounded by money.
As a sales representative for a major drug company, he was expected to entertain doctors two or three nights a week. There were seats in elaborate sporting events in private stadium suites at major games and dinners at five-star restaurants.
At that point, openly using gifts and money to influence doctors was considered standard practice.
But much of that came to a crashing halt after July 2002. That's when the pharmaceutical industry's trade group, known as PhRMA, published its Code on Interactions with Healthcare Professionals — voluntary guidelines that substantially changed the game for reps like Webb.
The free tickets were pulled, the tropical vacations abandoned, even branded trinkets were banished. But the practice of trying to influence doctors with money didn't disappear — it shifted.
Today when a rep like Webb wants to get a doctor to write prescriptions for his drug, there's still one almost foolproof way to get that task accomplished.
To get a doctor to write more prescriptions, Webb asks the doctor to become a speaker.
Earlier this week the investigative news organization ProPublica published a searchable database of doctors who have taken money from seven drug companies in the past two years. The database features over 17,000 doctors, many of whom are paid substantial sums of money to act as speakers for drug companies. But because only these seven drug companies have publicly reported the payments they give to physicians, those doctors represent only a small fraction of the doctors who actually speak for pharmaceutical companies in the U.S. Most estimates place the number of physician speakers somewhere in excess of 100,000.
Differing Views: Education Vs. Profit
On the surface, the act of speaking is a very straightforward transaction. The drug company gives the doctor a series of slides, sometimes some training in speaking, and then a date is set at a popular upscale restaurant where a roomful of other doctors gather over dinner and wine to listen to him talk.
The speaker is supposed to educate those other doctors about a drug's benefits and drawbacks, in the hope that they might prescribe the drug for their patients.
That, anyway, is how many of the doctors who do this speaking, see it.
"I'm going out there and trying to educate other doctors about how to treat ADHD appropriately and safely," says Lance Clawson, a child and adolescent psychiatrist in Maryland, who is in ProPublica's database.
Clawson's view of what he's doing is pretty typical. He says that though the money is nice, fundamentally he feels that he is doing a good deed by speaking. He points out that there are fewer than 9,000 child psychiatrists in America today, which means that children who struggle with problems like ADHD are mostly being treated by doctors who have no specialized training. "The fact that children are being treated for ADHD inappropriately is a really bad thing," Clawson says. "So I'm going out there and trying to teach people how to do a good job."
But the practice of doctor speaking looks much different from the other side of the fence, the side occupied by drug representatives. For the past month, NPR has talked to former and current representatives, 18 in all, and two are quoted in this story.
The representative we call Mathew Webb recently left the drug business and doesn't want us to use his real name out of fear of financial repercussions. Another representative we interview extensively, Angie Maher, left the industry two years ago after becoming a whistle-blower in a lawsuit.
The Role Of The 'Thought Leader'
According to Webb and Maher, Clawson's view that speaking is educational is not at all accidental. Drug companies train representatives to approach a narrow set of doctors in a very specific way, using language that deliberately fosters this idea that the doctors who speak are educators, and not just educators, but the smartest of the smart.
For example, every drug representative interviewed for this story used the exact same phrase when approaching a doctor with a pitch to become a speaker: Each doctor approached to speak was told that he was being recruited to serve as a "thought leader."
This phrase, Webb says, seems to have incredible psychological power.
"When you do say 'thought leader' I think it's a huge ego boost for the physicians," Webb says. "It's like a feather in their cap. They get a lot from it."
This is because most doctors have a very specific idea in mind when you ask them what constitutes a thought leader. Most doctors, including Clawson, cite two important qualifications. "First, the other doctors in the community respect that person's opinion," Clawson says. "And the other way to become a 'thought leader' is to become an academic researcher and try to push the bounds of science further, and then by definition you're a thought leader."
But some drug representatives, like Maher, have a more cynical view of why drug companies choose the doctors they choose. It's not about how well respected the doctor is, according to Maher; it's about how many prescriptions he writes.
"I think nowadays a thought leader is defined as a physician with a large patient population who can 
Webb points out that the people recruited to speak are almost always high prescribers with incredibly high patient populations. "That much money, easily," he says. "So yeah, it was a good return on investment."



To calculate return on investment, companies look at how much money was spent on a doctor compared with how much the company made from him in prescriptions. According to Maher and Webb, this is something companies monitor very closely.
"Whether it's a lunch, a dinner program — paying a physician to speak is tracked," Maher says.
Drug companies buy the doctors' prescription data from firms like IMS Health that use pharmacy records to track the prescriptions of almost every doctor in the U.S.
"So the way we could get to tell honestly if a speaker event was productive is you could look at their four-week data and see how many prescriptions more he wrote than he used to write," Webb says. "That's how we knew."
Do Doctors Know Their Prescribing Habits Change?
All of this raises a very thorny moral question: Do the doctors who do the speaking know that their prescribing habits have changed?
If they do know, then in a sense they're being bought — they are taking money to write prescriptions. If they don't, then they're unwittingly being played.
Dr. James Dickie, an endocrinologist in Westminster, Md., was very clear that his prescription-writing was unaffected by speaking. "Absolutely not. The physicians who are in the audience may notice it if they have been educated to that drug and the benefits of that drug — they may see an increase in writing. But specifically in my own? I don't believe so."
When NPR told Dickie about the findings learned from drug reps like Maher and Webb, he seemed genuinely surprised and disturbed and began to wonder out loud if he was, in fact, affected.
"It would really bother me," Dickie says. "Because I perceive myself as always prescribing in the best interest of my patient, and even unconsciously if I was unduly influenced, that would really bother me. I usually pride myself on keeping up my guard to prevent undue influence."
I perceive myself as always prescribing in the best interest of my patient, and even unconsciously if I was unduly influenced, that would really bother me. I usually pride myself on keeping up my guard to prevent undue influence.
But Maher says it's almost impossible for a doctor to keep up his guard. She points out that before doctors speak to their peers about a drug, they review slides provided by the company and talk to the company medical officers. And this process, she says, focuses the doctor on the most positive aspects of a drug.
"What is happening is that you are being manipulated to talk about the drug out loud," Maher says. "Kind of like talking themselves into knowing that what they were saying, were actually believing. And if they believed what they were saying, then they would write more drug."
Are Physicians Impervious?
David Switzer, a doctor in Virginia, writes about the interaction between doctors and reps on a popular website called cafepharma. As someone who has thought a lot about these issues, he says that he does not believe that most of the doctors who speak are conscious that their prescription-writing changes.
"The majority of doctors, I think, would honestly say, 'Oh that stuff doesn't work on me,' " Switzer says.
This attitude, he says is essentially programmed into them in medical school, where they're taught to think critically, and they're also taught that they have been taught to think critically. Which, in a way, Switzer says, handicaps them when it comes to drug reps.
"They come to the table with the belief that because they have gone through this rigorous academic training that they are somehow impervious," Switzer says. "I don't think that we're as good at that as we think that we are."
For his part, drug rep Webb says he can see the effects of this system, even in his own family. "My father has diabetes and I know one of his biggest complaints is that every time he goes to the doctor, it's: 'You know, let's try this medication this time. Let's try this medication this time.' And his diabetes is controlled — everything is working fine," Webb says.  "But his doctor's constantly changing him around, and he is a speaker — for several companies in our metropolitan area."
The drug industry's trade group, PhRMA, says that in its view, the current rules on speaking are "sufficient," and a spokesman for the group said the group was unaware of any direct evidence that paying a doctor to speak influences his prescribing habits.
Even so, a growing number of universities and hospitals no longer allow doctors who work on their staff to speak on behalf of drug companies. And under the new health law, by 2013, every doctor who takes money from a pharmaceutical company will be listed on a government website.
 

write a lot of pharmaceutical drugs. Period," she says.
Do the doctors who do the speaking know that their prescribing habits have changed? If they do know, then in a sense they're being bought. If they don't, then they're unwittingly being played.
This doesn't mean that every doctor recruited is not a high-quality doctor. Many are. But every representative NPR spoke to had a stable of stories about profoundly unimpressive doctors that they'd recruited as thought leaders essentially for the same reason that a robber robs a bank: because that's where the money is.
The fact is that the top 20 doctors in a representative's territory prescribe the vast majority of the medication. According to Webb, the top 20 percent prescribe as much as the lower 80.
So if you want to sell more of your product, and every representative is required to sell more, those are the physicians to target.
Which brings us to the hard reality about doctor speaking: Although doctors believe that they are recruited to speak in order to persuade a room of their peers to consider a drug, one of the primary targets of speaking, if not the primary target, is the speaker himself.
That's where reps look for a real increase in prescriptions — after a speech.
Following The Money
Here's how the money works out, at least for Webb. It's hard to know whether he's typical because there haven't been any published studies of this subject. But according to Webb, he would give a high-prescribing doctor about $1,500 to speak. And following that speech, Webb would see the speaking doctor write an additional $100,000 to $200,000 in prescriptions of his company's drug.

Doctors cash in on speeches

New Jersey-based doctors received more than $8.3 million in payments from pharmaceutical companies over the past 18 months for speeches promoting brand-label drugs to fellow doctors.

They were among the 17,000 doctors nationwide who were paid a total of $257.8 million by seven companies in 2009 and the first two quarters of 2010, according to data collected by ProPublica, a non-profit investigative news organization.
One doctor in Wayne — internist Thomas Dayspring — pocketed $203,200 during that period, making him the highest-paid speaker and consultant for the pharmaceutical firms in the state and the 37th highest paid in the country.
In Bergen and Passaic counties, 13 doctors who each earned more than $25,000 accounted for a combined $1 million in payments from drug firms. Many other local doctors received smaller payments.
"I’m one of the most requested speakers in the country and I’ve given over 800 speeches in continuing education, some of which were funded by the pharmaceutical companies," Dayspring said about the payments he received from GlaxoSmithKline. "I’m not some fly-by-night guy who doesn’t know what he’s doing. When I’m traveling, I’m not making any money in my practice, so the money I’m paid makes up for that."

The practice is legal, but some in the medical profession have raised questions about what they say is a perceived conflict of interest in having doctors promoting certain drugs to their peers and getting paid by the drug companies to do it. Former drug company employees and officials in the federal government have argued in several federal whistle-blower suits against drug companies that the companies use the speech payments as rewards for doctors who are prolific in prescribing their drugs.
"I’d be concerned about this if I were a patient," said Dr. Steven Nissen, a cardiovascular specialist at the Cleveland Clinic and a vocal opponent of the practice. "What does a patient want but to have their doctor be an advocate for them and their needs? But when they’re taking money from drug companies, the doctors are in effect working for those companies, and the interest of the drug companies may in fact be in conflict with the patient’s."
He said the drug company naturally wants to sell as much of its often expensive brand-label drug as possible, while a patient might be better served by a lower-priced generic drug that works equally well.
"It puts the physician in an unethical position," Nissen said.
Drug companies say the practice is designed to better serve patients by educating doctors about illnesses and the drugs available to combat them.
"AstraZeneca works with doctors so they can provide their colleagues information on appropriate use, safety and benefits of medication, and that’s beneficial to patients because doctors are better informed about our medicines and their treatment options," said Tony Jewell, an AstraZeneca spokesman.
Mary Anne Rhyne, a GlaxoSmithKline spokeswoman, agreed. "We participate so doctors can share their expertise about treatment options with their peers, to improve patient care," she said.


Credentials cited


Both companies say they restrict the speaker pool to doctors with certain credentials, such as an ongoing record of publishing in medical journals, a staff position at a teaching hospital and a leadership position with a national medical association.
Dayspring, who was paid for speaking engagements and educational programs, is an expert in cholesterol management and is director of the North Jersey Institute of Menopausal Lipidology.
Besides Dayspring, two other North Jersey doctors earned six figures from drug companies during the period studied: Dr. Joseph P. Valenza, a Saddle Brook pain medicine specialist and director of pain management at the Kessler Institute for Rehabilitation, earned $176,118, while Dr. Les A. Burns, a Wayne obstetrician and gynecologist, earned $136,150.
Messages were left Thursday at the offices of the 13 Bergen and Passaic doctors who earned the most money from the pharmaceutical companies. Three returned calls.
Oradell psychiatrist Sharad Wagle was paid $25,560 by AstraZeneca to speak and collect data from physicians around the country about a drug he declined to name. Wagle, chief of psychiatry at Holy Name Hospital in Teaneck, said he never advocated for a particular drug.

"People in different parts of the country react differently to drugs, so the company likes to collect as much information as it can — that’s how the drugs are improved," Wagle said.
Wagle said he resigned from consulting for AstraZeneca in August for personal reasons.
In all, AstraZeneca made nearly $22 million in payments to doctors in the first six months of this year, including $600,000 in payments to New Jersey doctors.
Burns, who spoke to doctors on behalf of GlaxoSmithKline about the benefits and risks for several drugs and a vaccine, said physicians are chosen by the drug companies based on their expertise. He declined to name the medicines that were the subject of his lectures.
"Not everyone gets to do this — it’s based on your credentials," Burns said. "The companies find doctors based on who is already using their drugs. And most companies have a cap as to how much they will pay one doctor."
GlaxoSmithKline used to limit doctors to $150,000 a year in payments for their speeches, but tightened the limit to $100,000 a year, after the company started posting its payment data on the Internet in December 2009, Rhyne said. The number of speakers has declined in the past year as well, she said.
The ProPublica database was compiled from information posted on the drug companies’ websites as well as the result of settlements in whistle-blower suits. The drug companies in the ProPublica database represent about a third of the $300 billion U.S. pharmaceutical market.
A report by ProPublica found that, nationally, hundreds of doctors paid by drug companies to speak had been accused of professional misconduct, were disciplined by state medical boards or lacked credentials as researchers or specialists. A Record review of disciplinary actions by the New Jersey Board of Medical Examiners found no record of actions against any of the North Jersey doctors who received significant money from drug companies.
In all, 384 of the 17,700 or so medical professionals across the nation in ProPublica’s database earned more than $100,000 during the 2009-10 period studied.
"That’s why this needs as much sunshine on it as possible," said Nissen. "For most working people to hear that doctors are making several hundred thousand dollars on the side is amazing. And they’re giving speeches using slides produced by the drug companies. They don’t even have to do any work."


Reporting payments


More than 70 drug companies do not currently reveal their payments to doctors, so the total amount paid out to doctors nationally is much higher. The federal health care reform law that Congress passed this year will require all drug companies to report their payments to doctors by 2013. The federal government will then post that information on the Web.
"We believe in providing more clarity and openness to the public, to doctors and to the government, and that it will lead to a higher level of trust between all the parties involved," said AstraZeneca’s Jewell.
Dayspring has no problem with the drug company payments’ being made public. "Being aboveboard is the way to go," he said.
Burns agreed. "I believe in what I do," he said. "I deserve everything I’ve earned and maybe a little more."

AP-GfK Poll: Americans split on health care repeal


First it was President Barack Obama's health care overhaul that divided the nation. Now it's the Republican cry for repeal.
An Associated Press-GfK poll found likely voters evenly split on whether the law should be scrapped or retooled to make even bigger changes in the way Americans get their health care.
Tea party enthusiasm for repeal has failed to catch on with other groups, the poll found, which may be a problem for Republicans vowing to strike down Obama's signature accomplishment if they gain control of Congress in the Nov. 2 elections.
Among likely voters, 36 percent said they want to revise the law so it does more to change the health care system. A nearly identical share — 37 percent — said they want to repeal it completely.
"We just can't ignore the health of people in our country. ... It would be an even bigger drain on the economy," said Linda Montgomery, 63, a retired software engineer from Pass Christian, Miss. "I wouldn't oppose having the law changed — I would like to see it expanded even more."
But Joe Renier, an information technology manager, said he finds that view "actually quite scary."
"They want more power for the government," said Renier, 54, of Tucson, Ariz. "I don't believe the government has a right to tell us to buy health insurance," he said, adding that the law does nothing to address unsustainable health care costs.
In the poll, only 15 percent said they would leave the overhaul as it is. And 10 percent wanted modifications to narrow its scope.
The health care law will eventually extend coverage to more than 30 million uninsured by signing up low-income adults for Medicaid and providing middle-class households with tax credits for private insurance. Starting in 2014, most Americans will be required to carry coverage, and insurers no longer will be allowed to turn away people in poor health.
Overall, Americans remain divided about the changes. Among likely voters, 52 percent oppose the legislation, compared with 41 percent who said they support it. Strong opponents outnumber strong supporters by 2-to-1.
Health care remained among the top issues for Americans in the poll, ahead of concerns about terrorism. But Democrats are losing their edge when it comes to whom the public trusts as stewards of the health care system. Among likely voters, there was essentially no difference, with 46 percent saying they trust Obama and the Democrats, and 47 percent saying they trust Republicans.
"Seven months after they passed this bill, there is no consensus about its future," said Robert Blendon, a Harvard University public health professor who follows opinion trends on health care. "Neither side is a strong winner when it comes to the future."
The tea party movement remains a crucible of opposition. More than 7 in 10 likely voters who back the tea party said the law should be repealed in its entirety.
But the poll found that strong opponents are vastly different from nearly all others. Most strong opponents favor complete repeal, while majorities of those who are neutral or who moderately oppose the legislation say leave it as is or expand it.
Only 26 percent of women favored repealing the law. That restraint was evident even among Republican women — 52 percent supported repeal, compared with 68 percent of Republican men.
People under age 30 were the most likely to say the law should be expanded to do more.
"Eventually, a public option does need to be put into it," said Mark Slack, 23, of Charleston, S.C., referring to an Obama-backed proposal for a government plan to compete with private insurance that failed for lack of sufficient congressional support.
"The health care law may not be perfect, but it does represent an improvement that can be built on," said Slack, a graduate student who wants to teach high school English. "I'm not sure that we need to be subsidizing the insurance companies as we're doing in this bill."
Older people were more likely to favor complete repeal, with 38 percent of seniors giving the legislation a thumbs down. Much of the financing to expand coverage for workers and their families is coming from Medicare, with cuts to hospitals, nursing homes, insurers and other providers that nonpartisan experts have warned are politically unsustainable.
But Mary Ann O'Connell, 67, said the main reason she's in favor of repeal is the fine, starting in 2014, on those who fail to get coverage through an employer, a government program or by purchasing their own plan. Her 40-year-old daughter was hit with a similar penalty this year in Massachusetts, a state that already has adopted its own health care remake and served as a model for the federal plan.
"It's going to do a lot of harm to people who don't have a lot of money, because they're going to get the fine and they still won't have insurance," said O'Connell, a retired teacher living in the Boston suburbs.
The AP-GfK Poll was conducted Oct. 13-18 by GfK Roper Public Affairs and Corporate Communications. It involved


As Breast Cancer Awareness Month continues, a new law is about to go into effect in New York that will help patients make the best decision with all their post-surgery options.
A new law passed that will require hospitals to give women undergoing mastectomies all their options when it comes to reconstructive surgery, CBS 2’s Cindy Hsu reports.
State Senator Malcolm Smith (D) said there’s a huge disparity on what information and treatment women are getting depending on their health coverage.
“You have 11 percent of women who are on Medicare who are actually getting the reconstructive surgery and the information as opposed to managed care. It’s up to 54 percent,” Smith said.
The new law also requires doctors to let patients know where they can get reconstructive surgery.
“There’s now dearly a dozen various breast reconstruction help that’s available to the patient,” Dr. Kaveh Alizadeh of the Long Island Plastic Surgical Group said.
Now, breast cancer survivor Leslie Reid knows that other victims of the deadly disease will have more hope once they come out of surgery.
“You wake up in the hospital, and you’ve had a double mastectomy, it’s like a wall hit you,” said Reid, who was diagnosed two years ago. “I just felt there wasn’t enough information given to me so I just sat in front of my computer and googled every possible option that I had.”
Ivis Febus-Sampavo, a 17-year breast cancer survivor, said that many women in low-income and minority communities that slip through the cracks will get a chance to have their questions answered.
“If you speak Spanish, imagine being diagnosed with breast cancer, you go through that shock and then you don’t realize what your options are, you may not ask the right questions you may not feel you have the right to ask these questions,” said Febus-Sampavo, who works for Latina SHARE, a New York City-group that raises breast cancer awareness for Latina communities.
The new law puts hospitals on notice and will empower women to know they’re entitled to answers and options, she added.
The new law will go into effect Jan. 1
New Jersey and Connecticut also have legislation aimed at giving women the information and time they need to make informed decisions on breast cancer treatment options.
from-
NEW YORK (CBS 2

Share

Twitter Delicious Facebook Digg Stumbleupon Favorites More